When: Confirmed breakout above $278 on volume ≥18M with positive MACD histogram

Then: Full re-engagement at benchmark weight

When: 50 SMA at $262 fails on daily close with volume >16M

Then: Trim toward 60% benchmark weight

Underweight to ~70% of benchmark weight; trim into 273-278 zone; stop at 258; re-engage on breakout above 278 with volume >18M and positive MACD histogram, or on pullback to 262-264 zone (50 SMA/Bollinger band confluence)

• Three independent risk vectors converging: valuation asymmetry, technical deterioration, and binary event risk
• Valuation: 22 forward P/E on mid-single-digit grower with beta 0.24 is priced for perfection; defensive scarcity premium breaks down at 5% 10-year with stagflation-overheating regime risk
• Technical: lower highs sequence (278, 273, 271, 269), ATR compressed from 6.46 to 5.24, MACD histogram negative for 11 straight sessions
• Event risk: Trump healthcare announcement today with 100% Polymarket probability of pharma language; punitive headlines risk 3-7% gap, even benign-ambiguous headlines risk 2-3% air-pocket
• CFO above-target growth commentary is unvalidated anecdote without segment-level data
• DePuy Synthes $20B divestiture takes 9-18 months with antitrust review; partial rumor already priced; remaining upside small relative to deal-break risk
• 1.98% dividend yield is a yield trap in 5% 10-year environment; yield not competitive with risk-free rates
• Pipeline (Tremfya, Darzlex, Carvykti, Caplyta) offsets Stelara erosion over 3-5 years, not 1-2 quarters
• 60-year dividend streak and AAA balance sheet cited by neutral analyst justify franchise quality, not entry-point quality at current levels

→ vs aggressive: Base case target of 245-250 is a tail outcome, not central expectation; stop will be tested by event-driven air pockets rather than tape

→ vs neutral: HOLD with full benchmark weight is paying full price for an option we should not be writing; doing nothing at 270 is complacency dressed in long-term investing language

→ vs aggressive: Framing of 'risking one to make two' toward 245 is trader talk, not risk management; does not account for event-driven volatility in low-volatility name

→ vs neutral: Bridge-year risk acknowledged in single line but treated as core reason for underweight positioning; neutral framing underweights this

→ vs aggressive: CFO commentary is management statement without quantitative guidance or segment bridge; 4-6% revenue growth for 4 years is the anchor

→ vs neutral: 1.98% yield is not sanctuary in 5% 10-year; defensive income thesis requires rates falling or stable with scarce growth

SELL refined; execute trim in increments into 273-278, widen stop to 256, maintain 70% benchmark weight with flexibility to range 60-90% based on price action

• 22 times forward earnings on mid-single-digit grower with negative spread to 5% 10-year does not reward multiple expansion
• ATR compressed from 6.46 to 5.24 indicates volatility drying up rather than breaking down; lower-high sequence on contracting volatility is categorically different from distribution without volume confirmation
• Aggressive analyst's re-engagement framework is internally inconsistent: trim into 273-278 resistance while waiting for breakout above 278 creates whipsaw risk
• Aggressive 245-250 target requires 9-10% drop without a clean fundamental catalyst path; FCF coverage of 1.56x on dividend, AAA balance sheet, and 19.3B in FCF bounds the downside
• Conservative analyst's yield trap framing is too narrow; JNJ generates 19B in cash annually that compounds through balance sheet regardless of rate environment
• Stelara offset already partially priced into forward EPS of 12.29 versus TTM EPS of 8.62; market is aware of pipeline risk
• Event risk dimension massively underweighted; ambiguity in Trump healthcare headlines is modal outcome and worst case for crowded defensive longs, capable of producing 2-3% air-pocket
• Zero Reddit/retail sentiment indicates institutional-only rally driven by defensive rotation thesis, limiting tail risk but also removing sentiment floor
• Macro regime (5% 10-year, 95% no Fed cuts 2026, 76% overheating probability) is fundamentally range-bound for defensives: bid on volatility, sold on stability
• JNJ at 270 with 4.5% earnings yield versus 5% 10-year is at equilibrium; direction requires catalyst not thesis
• Position sizing should be function of price action: add to 80-90% if 262-264 zone holds on retest with positive breadth, trim to 60% if 50 SMA at 262 fails on daily close with volume above 16M
• Re-entry trigger: 262-264 zone (50 SMA confluence with lower Bollinger band) is better risk-reward than breakout above 278 because it offers tested support with momentum reset
• 245-250 is level where you want to be buyer, not trimmer; aggressive analyst conflates tactical trim with strategic re-entry

→ vs aggressive: Conflates tactical trim with strategic re-entry; treating 245 as target trim level rather than buy zone misapplies the framework

→ vs conservative: Yield trap framing is too narrow; 1.98% dividend yield reflects quality franchise floor, not investment thesis; FCF of 19.3B compounds through balance sheet regardless of 10-year yield

→ vs conservative: Claims conservative position but agrees with direction, 70% target, entry zone, and stop; only disagrees on downside target which trader's plan already doesn't anchor to; this is disagreement over how bearish, not genuine conservatism

→ vs conservative: Dismissed Stelara offset too quickly; forward EPS of 12.29 already represents Street's best estimate of post-Stelara earnings normalization, suggesting risk is largely priced in